Sebastián Videla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sebastián Videla has a total of 606 co-authors. Here are the top co-authors by number of shared publications:
- Thiago Carnaval
Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, Institute of Neurosciences University of Barcelona L'Hospitalet de Llobregat Spain
15 shared publications Bonaventura Clotet
Fight AIDS and Infectious Diseases Foundation, Badalona, Spain
12 shared publicationsGuillem Sirera
Lluita Contra La SIDA Foundation and AIDS Unit, University Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain
10 shared publications- Elena Iborra
Angiology and Vascular Surgery Department, Hospital Universitari de Bellvitge; IDIBELL-BIOHEART; Department of Clinical Sciences, School of Medicine, University of Barcelona
5 shared publications Eric Sicard
Algorithme Pharma, 1200, Beaumont Avenue, Montreal, H3P 3P1, Canada
5 shared publications- Jesús Villoria
Department of Statistical Design and Biometrics, Medicxact SL, Alpedrete, Spain
5 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
Ischemic complications after preoperative arterial embolization in pancreatectomy with arterial resection: lessons learned from 14 years institutional experience with a narrative review
Background: Preoperative arterial embolization (PAE) of the celiac trunk or hepatic artery may promote recruitment of collateral circulation and thereby prevent hepatic ischemia during pancreatic surgery for locally advanced pancreatic cancer requiring arterial resection (AR) without the need for reconstruction. Despite its theoretical benefits, the role of PAE still remains unclear. Moreover, embolization of variant hepatic arteries before pancreatoduodenectomy (PD), common hepatic artery (CHA) embolization before distal pancreatectomy with celiac axis resection (DP-CAR), and PAE as an adjunct to complex vascular resections represent anatomically and clinically distinct scenarios. Methodology: A retrospective single-center analysis was performed to identify patients who underwent PAE prior to pancreatic resection with AR. Patients who did not subsequently undergo pancreatic resection were excluded. The final cohort was stratified into three groups: hepatic artery embolization before PD with arterial resection, CHA embolization before DP-CAR, and PAE as an adjunct to complex or extended vascular resection. Technical complications related to embolization, arterial thrombosis, ischemic complications, major morbidity, reoperation, and mortality were analyzed descriptively. Results: Thirty-four patients underwent PAE; eight did not subsequently undergo pancreatic resection, leaving 26 patients for analysis. A total of 28 embolization sessions were performed. Thirteen patients underwent hepatic artery embolization before PD with arterial resection, eight underwent CHA embolization before DP-CAR, and five underwent PAE before complex or extended vascular resection. Six patients (23.1%) experienced at least one technical, thrombotic, and/or ischemic event: 0/13 (0%) in the PD group, 4/8 (50.0%) in the DP-CAR group, and 2/5 (40.0%) in the complex/extended resection group. Major morbidity (Clavien–Dindo ≥IIIb) occurred in 7/26 patients (26.9%), and 5/26 (19.2%) required reoperation. Thirty- and 90-day mortality were both 2/26 (7.7%). All arterial reconstructions were planned preoperatively, and no unplanned arterial reconstruction was required. Conclusion: PAE before pancreatic arterial resection encompasses distinct clinical strategies that should not be considered equivalent. No technical, thrombotic, or ischemic events occurred after hepatic artery embolization before PD in this series, whereas such events were observed after CHA embolization before DP-CAR and complex vascular resections. Given the small heterogeneous cohort, absence of a comparator group, and non-standardized assessment of collateral perfusion, these findings cannot establish a protective effect of PAE or determine its contribution to subsequent ischemic events. PAE should therefore be considered an individualized adjunct within the overall vascular surgical strategy.
- 15 October 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
Open AccessIschemic complications after preoperative arterial embolization in pancreatectomy with arterial resection: lessons learned from 14 years institutional experience with a narrative review
Background: Preoperative arterial embolization (PAE) of the celiac trunk or hepatic artery may promote recruitment of collateral circulation and thereby prevent hepatic ischemia during pancreatic surgery for locally advanced pancreatic cancer requiring arterial resection (AR) without the need for reconstruction. Despite its theoretical benefits, the role of PAE still remains unclear. Moreover, embolization of variant hepatic arteries before pancreatoduodenectomy (PD), common hepatic artery (CHA) embolization before distal pancreatectomy with celiac axis resection (DP-CAR), and PAE as an adjunct to complex vascular resections represent anatomically and clinically distinct scenarios. Methodology: A retrospective single-center analysis was performed to identify patients who underwent PAE prior to pancreatic resection with AR. Patients who did not subsequently undergo pancreatic resection were excluded. The final cohort was stratified into three groups: hepatic artery embolization before PD with arterial resection, CHA embolization before DP-CAR, and PAE as an adjunct to complex or extended vascular resection. Technical complications related to embolization, arterial thrombosis, ischemic complications, major morbidity, reoperation, and mortality were analyzed descriptively. Results: Thirty-four patients underwent PAE; eight did not subsequently undergo pancreatic resection, leaving 26 patients for analysis. A total of 28 embolization sessions were performed. Thirteen patients underwent hepatic artery embolization before PD with arterial resection, eight underwent CHA embolization before DP-CAR, and five underwent PAE before complex or extended vascular resection. Six patients (23.1%) experienced at least one technical, thrombotic, and/or ischemic event: 0/13 (0%) in the PD group, 4/8 (50.0%) in the DP-CAR group, and 2/5 (40.0%) in the complex/extended resection group. Major morbidity (Clavien–Dindo ≥IIIb) occurred in 7/26 patients (26.9%), and 5/26 (19.2%) required reoperation. Thirty- and 90-day mortality were both 2/26 (7.7%). All arterial reconstructions were planned preoperatively, and no unplanned arterial reconstruction was required. Conclusion: PAE before pancreatic arterial resection encompasses distinct clinical strategies that should not be considered equivalent. No technical, thrombotic, or ischemic events occurred after hepatic artery embolization before PD in this series, whereas such events were observed after CHA embolization before DP-CAR and complex vascular resections. Given the small heterogeneous cohort, absence of a comparator group, and non-standardized assessment of collateral perfusion, these findings cannot establish a protective effect of PAE or determine its contribution to subsequent ischemic events. PAE should therefore be considered an individualized adjunct within the overall vascular surgical strategy.
- Open Access
- 3 July 2026
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 10 (4)
Cost-effectiveness of angiography-guided thyroidectomy to prevent postoperative hypoparathyroidism: Spanish National Health System model-based analysis
Background: Postoperative hypoparathyroidism is the most common complication after total thyroidectomy, and is associated with impaired quality of life and increased long-term healthcare use. Indocyanine green fluorescence imaging enables real-time intraoperative assessment of parathyroid perfusion, potentially improving gland preservation. However, its cost-effectiveness in routine surgical practice has not been formally evaluated. Methods: A model-based cost-effectiveness analysis was conducted comparing angiography-guided thyroidectomy with conventional thyroidectomy from the perspective of the Spanish National Health System. A state-transition Markov model simulated long-term outcomes for adults undergoing thyroidectomy, incorporating the incidence of transient and permanent hypoparathyroidism, health-related quality-adjusted life-years, and direct medical costs. The model used contemporary surgical data, included a 35-year time horizon, and discounted costs and effects at 3.5% annually. Probabilistic and deterministic sensitivity analyses were used to assess parameter and structural uncertainty. Cost-effectiveness was judged at a willingness-to-pay threshold of €30 000 per quality-adjusted life-year. Results: Angiography-guided thyroidectomy was associated with lower lifetime healthcare costs (€563.7 million versus €613.2 million) and greater health benefits (310 997 versus 299 107 quality-adjusted life-years), yielding a gain of 11 889 quality-adjusted life-years and €49.5 million in cost savings. Angiography-guided thyroidectomy dominated conventional thyroidectomy in all sensitivity analyses, with an incremental net monetary benefit of €406.2 million (95% uncertainty interval €381.7 million to €431.5 million). Scenario and joint probabilistic analyses confirmed robustness under alternative utility values and surgical outcomes. Conclusion: Angiography-guided thyroidectomy may be a cost-saving innovation within publicly funded healthcare systems by reducing the incidence and chronic burden of postoperative hypoparathyroidism. These findings support broader adoption of fluorescence-guided surgery and underscore the need for real-world implementation studies to validate cost-effectiveness, and inform training and procurement strategies.
- 3 July 2026
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 10 (4)
Open AccessCost-effectiveness of angiography-guided thyroidectomy to prevent postoperative hypoparathyroidism: Spanish National Health System model-based analysis
Background: Postoperative hypoparathyroidism is the most common complication after total thyroidectomy, and is associated with impaired quality of life and increased long-term healthcare use. Indocyanine green fluorescence imaging enables real-time intraoperative assessment of parathyroid perfusion, potentially improving gland preservation. However, its cost-effectiveness in routine surgical practice has not been formally evaluated. Methods: A model-based cost-effectiveness analysis was conducted comparing angiography-guided thyroidectomy with conventional thyroidectomy from the perspective of the Spanish National Health System. A state-transition Markov model simulated long-term outcomes for adults undergoing thyroidectomy, incorporating the incidence of transient and permanent hypoparathyroidism, health-related quality-adjusted life-years, and direct medical costs. The model used contemporary surgical data, included a 35-year time horizon, and discounted costs and effects at 3.5% annually. Probabilistic and deterministic sensitivity analyses were used to assess parameter and structural uncertainty. Cost-effectiveness was judged at a willingness-to-pay threshold of €30 000 per quality-adjusted life-year. Results: Angiography-guided thyroidectomy was associated with lower lifetime healthcare costs (€563.7 million versus €613.2 million) and greater health benefits (310 997 versus 299 107 quality-adjusted life-years), yielding a gain of 11 889 quality-adjusted life-years and €49.5 million in cost savings. Angiography-guided thyroidectomy dominated conventional thyroidectomy in all sensitivity analyses, with an incremental net monetary benefit of €406.2 million (95% uncertainty interval €381.7 million to €431.5 million). Scenario and joint probabilistic analyses confirmed robustness under alternative utility values and surgical outcomes. Conclusion: Angiography-guided thyroidectomy may be a cost-saving innovation within publicly funded healthcare systems by reducing the incidence and chronic burden of postoperative hypoparathyroidism. These findings support broader adoption of fluorescence-guided surgery and underscore the need for real-world implementation studies to validate cost-effectiveness, and inform training and procurement strategies.
- Open Access
Acetylsalicylic Acid and Ibuprofen as Adjunctive Therapy for Tuberculosis
Background: As novel strategies are needed to improve tuberculosis (TB) outcomes and shorten treatment; we evaluated whether host-directed therapy with non-steroidal anti-inflammatory drugs (NSAIDs) could enhance treatment response when added to standard therapy. Methods: We conducted a phase 2b, double-blind, placebo-controlled, randomized trial in South Africa and Georgia. Adults with microbiologically confirmed pulmonary TB were randomized to receive standard therapy plus acetylsalicylic acid (ASA) (300 mg), ibuprofen (IBU) (400 mg), or placebo twice daily for 4 weeks and once daily for 4 weeks. Primary end points were time to a 67% reduction in the clinical symptom/sign-based TB score (TBS) and time to stable sputum culture conversion (SCC). Safety and clinical, radiological and microbiological assessments were performed up to 24 weeks after treatment completion. Results: Of 221 randomized participants, 204 were included in the analysis. No significant differences were observed in the primary end points; median time to 67% TBS reduction was 4.5 weeks (ASA) and 5.0 weeks (IBU and placebo), and median time to stable SCC was 8 weeks in all groups. Both NSAIDs were associated with earlier cavity resolution at week 8, sustained at week 24 for ASA. IBU was associated with greater clinical improvement in multidrug-resistant-TB. Adverse event rates were similar across arms. Conclusions: Adjunctive ASA and IBU did not shorten the time to clinical or microbiologic response but were associated with earlier cavity resolution and improved TBS in specific subgroups, with similar safety to standard therapy alone. Funded by the European Union’s Horizon 2020; ClinicalTrials.gov number, NCT04575519 .
Open AccessAcetylsalicylic Acid and Ibuprofen as Adjunctive Therapy for Tuberculosis
Background: As novel strategies are needed to improve tuberculosis (TB) outcomes and shorten treatment; we evaluated whether host-directed therapy with non-steroidal anti-inflammatory drugs (NSAIDs) could enhance treatment response when added to standard therapy. Methods: We conducted a phase 2b, double-blind, placebo-controlled, randomized trial in South Africa and Georgia. Adults with microbiologically confirmed pulmonary TB were randomized to receive standard therapy plus acetylsalicylic acid (ASA) (300 mg), ibuprofen (IBU) (400 mg), or placebo twice daily for 4 weeks and once daily for 4 weeks. Primary end points were time to a 67% reduction in the clinical symptom/sign-based TB score (TBS) and time to stable sputum culture conversion (SCC). Safety and clinical, radiological and microbiological assessments were performed up to 24 weeks after treatment completion. Results: Of 221 randomized participants, 204 were included in the analysis. No significant differences were observed in the primary end points; median time to 67% TBS reduction was 4.5 weeks (ASA) and 5.0 weeks (IBU and placebo), and median time to stable SCC was 8 weeks in all groups. Both NSAIDs were associated with earlier cavity resolution at week 8, sustained at week 24 for ASA. IBU was associated with greater clinical improvement in multidrug-resistant-TB. Adverse event rates were similar across arms. Conclusions: Adjunctive ASA and IBU did not shorten the time to clinical or microbiologic response but were associated with earlier cavity resolution and improved TBS in specific subgroups, with similar safety to standard therapy alone. Funded by the European Union’s Horizon 2020; ClinicalTrials.gov number, NCT04575519 .
- Open Access
- 24 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (23) , 8347
High-Flow Nasal Oxygenation During Sedation for Transcatheter Aortic Valve Replacement: The HIGH-OXY-TAVR Randomised–Controlled Trial
Background: Data on high flow nasal oxygenation (HFNO) efficacy in hypoxia prevention in transcatheter aortic valve replacement (TAVR) are conflictive. We aimed to determine the benefit of HFNO in preventing the occurrence of desaturations during TAVR. Methods: An investigator-initiated, proof of concept, single-centre, randomised, and controlled trial on 132 adult patients who were scheduled to undergo transfemoral TAVR was conducted. Patients were randomised (1:1) to HFNO (H-group) with a flow rate of 50 L min−1 and FiO2 0.6 or standard of care oxygen therapy (S-group). The primary endpoint was the number of patients with a desaturation episode (SpO2 < 93%) for >10 s during TAVR. Secondary outcomes included arterial partial pressure of oxygen (pO2) 45 min from sedation start and changes in glomerular filtration rate from baseline to 12 h post-procedure. Results: Between 23 November and 24 July, a per-protocol analysis was performed in a total of 125 patients (H-group n = 64; S- group n = 61; 49 females). The number of patients with any desaturation episode was significantly lower in the H-group [13/64 (20%, 95% CI: 12–32%)] than in the S-group [31/61 (51%, 95% CI: 39–63%), RR: 0.39 (95%CI: 0.23–0.68)]. At 45 min, mean (SD) pO2 was higher in the H-group (24(9.8) kPa vs. 16.7(7.5) kPa; p < 0.005). A significant improvement in delta median (IQR) difference on glomerular filtration rate was observed in the H-group [1.6(−1–7.9) mL min−1 1.73 m−2] with respect to the S-group [0.2(−6.1–3.1) mL min−1 1.73 m−2; p-value: 0.013]. Conclusions: This trial demonstrated that HFNO provides a better oxygenation pattern than standard oxygen therapy during TAVR. Larger studies focusing on long-term clinical outcomes are warranted to evaluate the benefit of HFNO during sedation for TAVR procedures.
- 24 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (23) , 8347
Open AccessHigh-Flow Nasal Oxygenation During Sedation for Transcatheter Aortic Valve Replacement: The HIGH-OXY-TAVR Randomised–Controlled Trial
Background: Data on high flow nasal oxygenation (HFNO) efficacy in hypoxia prevention in transcatheter aortic valve replacement (TAVR) are conflictive. We aimed to determine the benefit of HFNO in preventing the occurrence of desaturations during TAVR. Methods: An investigator-initiated, proof of concept, single-centre, randomised, and controlled trial on 132 adult patients who were scheduled to undergo transfemoral TAVR was conducted. Patients were randomised (1:1) to HFNO (H-group) with a flow rate of 50 L min−1 and FiO2 0.6 or standard of care oxygen therapy (S-group). The primary endpoint was the number of patients with a desaturation episode (SpO2 < 93%) for >10 s during TAVR. Secondary outcomes included arterial partial pressure of oxygen (pO2) 45 min from sedation start and changes in glomerular filtration rate from baseline to 12 h post-procedure. Results: Between 23 November and 24 July, a per-protocol analysis was performed in a total of 125 patients (H-group n = 64; S- group n = 61; 49 females). The number of patients with any desaturation episode was significantly lower in the H-group [13/64 (20%, 95% CI: 12–32%)] than in the S-group [31/61 (51%, 95% CI: 39–63%), RR: 0.39 (95%CI: 0.23–0.68)]. At 45 min, mean (SD) pO2 was higher in the H-group (24(9.8) kPa vs. 16.7(7.5) kPa; p < 0.005). A significant improvement in delta median (IQR) difference on glomerular filtration rate was observed in the H-group [1.6(−1–7.9) mL min−1 1.73 m−2] with respect to the S-group [0.2(−6.1–3.1) mL min−1 1.73 m−2; p-value: 0.013]. Conclusions: This trial demonstrated that HFNO provides a better oxygenation pattern than standard oxygen therapy during TAVR. Larger studies focusing on long-term clinical outcomes are warranted to evaluate the benefit of HFNO during sedation for TAVR procedures.
- Open Access
- 10 November 2025
- Published by Wolters Kluwer Health in Medicine: Case Reports and Study Protocols
- Vol. 6 (6) , e00386
Estimating the prevalence of chronic insomnia in patients with non-cancer chronic pain: Study protocol of a multicenter cross-sectional study
Background: Chronic non-cancer pain (CNCP) and insomnia frequently co-occur, creating a bidirectional cycle in which pain disrupts sleep, and poor sleep heightens pain perception. Despite mounting evidence suggesting high comorbidity, no studies have explored this relationship in the Spanish population. This study aims to estimate the prevalence of chronic insomnia among CNCP patients and examine its associations with pain intensity, sleep quality, psychological symptoms, and medication use. Methods and analysis: This will be a multicenter, cross-sectional prevalence study involving 15 pain units across Catalonia, Spain. Adult patients with a known CNCP diagnosis under specialist care will be invited to participate. Data will be collected during a single study visit using electronic medical records and a structured battery of validated self-report questionnaires, including the Insomnia Severity Index, Brief Pain Inventory, Pittsburgh Sleep Quality Index, Hospital Anxiety and Depression Scale, Profile of Mood States, short form-12 health survey, and EuroQol-5 Dimensions-3 Level. The primary outcome is the prevalence of chronic insomnia. Secondary outcomes include associations with pain severity, sleep quality, mood, quality of life, and hypnotic drug use. Descriptive statistics and Poisson regression with robust variance will be used to estimate prevalence ratios and 95% confidence intervals. Ethics and dissemination: The study has received ethical approval from the coordinating site ( Hospital del Mar Research Institute ; reference 2025/11914) and will obtain local approvals at participating centers. Informed consent will be obtained from all participants. Results will be disseminated via peer-reviewed journals and scientific conferences, regardless of outcome.
- 10 November 2025
- Published by Wolters Kluwer Health in Medicine: Case Reports and Study Protocols
- Vol. 6 (6) , e00386
Open AccessEstimating the prevalence of chronic insomnia in patients with non-cancer chronic pain: Study protocol of a multicenter cross-sectional study
Background: Chronic non-cancer pain (CNCP) and insomnia frequently co-occur, creating a bidirectional cycle in which pain disrupts sleep, and poor sleep heightens pain perception. Despite mounting evidence suggesting high comorbidity, no studies have explored this relationship in the Spanish population. This study aims to estimate the prevalence of chronic insomnia among CNCP patients and examine its associations with pain intensity, sleep quality, psychological symptoms, and medication use. Methods and analysis: This will be a multicenter, cross-sectional prevalence study involving 15 pain units across Catalonia, Spain. Adult patients with a known CNCP diagnosis under specialist care will be invited to participate. Data will be collected during a single study visit using electronic medical records and a structured battery of validated self-report questionnaires, including the Insomnia Severity Index, Brief Pain Inventory, Pittsburgh Sleep Quality Index, Hospital Anxiety and Depression Scale, Profile of Mood States, short form-12 health survey, and EuroQol-5 Dimensions-3 Level. The primary outcome is the prevalence of chronic insomnia. Secondary outcomes include associations with pain severity, sleep quality, mood, quality of life, and hypnotic drug use. Descriptive statistics and Poisson regression with robust variance will be used to estimate prevalence ratios and 95% confidence intervals. Ethics and dissemination: The study has received ethical approval from the coordinating site ( Hospital del Mar Research Institute ; reference 2025/11914) and will obtain local approvals at participating centers. Informed consent will be obtained from all participants. Results will be disseminated via peer-reviewed journals and scientific conferences, regardless of outcome.
- Open Access
- 12 October 2025
- Published by Springer Nature in Research Square
Periodontal disease and glaucoma. A systematic review and Meta-Analysis
Topic To assess the association between periodontal disease and glaucoma in adults through systematic review and meta-analysis of observational studies. Clinical relevance This study suggests that periodontal disease may increase the likelihood of developing glaucoma. Recognizing oral health as a potential modifiable risk factor could promote interdisciplinary prevention strategies and earlier detection of glaucoma in at-risk individuals. Methods This review followed PRISMA 2020 guidelines and was registered in PROSPERO (CRD42023428738). A systematic search was performed in PubMed/Medline, Scopus, Web of Science, Embase, Cochrane Library, LILACS, Google Scholar and journals with the highest impact in Ophthalmology, available until August 26th, 2025. Eligible articles were independently screened and quality assessed by three reviewers. All observational clinical studies reporting quantitative effect estimates and 95% confidence interval (95%CI) for the association between periodontal disease and glaucoma were included. Effect estimates for the association with glaucoma were pooled using random effects meta-analysis (Review Manager Version 5.4). Results 946 studies were screened, and 6 studies were included in the systematic review: 3 cohort studies, 1 nested case-control study and 2 cross-sectional studies. The populations evaluated were adults (n = 1,153,308). Different diagnostic methods were used for periodontal disease and glaucoma (clinical, self-reported, and disease classification codes), with variations in the criteria used and the type of glaucoma evaluated. Pooled effect estimates indicated a positive association between periodontal disease and glaucoma (OR: 1.72; 95%CI: 1.13–2.63; p-value: 0.010, I2: 99%). Conclusion The findings of this review, based on observational studies involving over one million individuals, suggest an association between periodontal disease and glaucoma. Patients with periodontal disease appear to be more likely to develop glaucoma than patients without it. However, additional long-term studies are needed.
- 12 October 2025
- Published by Springer Nature in Research Square
Open AccessPeriodontal disease and glaucoma. A systematic review and Meta-Analysis
Topic To assess the association between periodontal disease and glaucoma in adults through systematic review and meta-analysis of observational studies. Clinical relevance This study suggests that periodontal disease may increase the likelihood of developing glaucoma. Recognizing oral health as a potential modifiable risk factor could promote interdisciplinary prevention strategies and earlier detection of glaucoma in at-risk individuals. Methods This review followed PRISMA 2020 guidelines and was registered in PROSPERO (CRD42023428738). A systematic search was performed in PubMed/Medline, Scopus, Web of Science, Embase, Cochrane Library, LILACS, Google Scholar and journals with the highest impact in Ophthalmology, available until August 26th, 2025. Eligible articles were independently screened and quality assessed by three reviewers. All observational clinical studies reporting quantitative effect estimates and 95% confidence interval (95%CI) for the association between periodontal disease and glaucoma were included. Effect estimates for the association with glaucoma were pooled using random effects meta-analysis (Review Manager Version 5.4). Results 946 studies were screened, and 6 studies were included in the systematic review: 3 cohort studies, 1 nested case-control study and 2 cross-sectional studies. The populations evaluated were adults (n = 1,153,308). Different diagnostic methods were used for periodontal disease and glaucoma (clinical, self-reported, and disease classification codes), with variations in the criteria used and the type of glaucoma evaluated. Pooled effect estimates indicated a positive association between periodontal disease and glaucoma (OR: 1.72; 95%CI: 1.13–2.63; p-value: 0.010, I2: 99%). Conclusion The findings of this review, based on observational studies involving over one million individuals, suggest an association between periodontal disease and glaucoma. Patients with periodontal disease appear to be more likely to develop glaucoma than patients without it. However, additional long-term studies are needed.
- Open Access
- 21 August 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e64450
Hemodynamic Assessment of Arterial Perfusion by Using the Ultrasonographic Hand Acceleration Time: Protocol for a Cross-Sectional Prospective Descriptive Study
Background: Several noninvasive methods can be used to assess hand perfusion, but none have been standardized for diagnosing chronic upper limb ischemia. One potentially useful diagnostic tool for this purpose is the ultrasonographic hand acceleration time (HAT), although it still requires characterization and validation. Objective: This study aims to describe the technique for assessing hand perfusion through HAT while quantifying it in patients with chronic upper limb ischemia and healthy volunteers. Methods: This prospective, cross-sectional, and descriptive study evaluates HAT measurements by using vascular duplex ultrasound (DUS), a novel technique for assessing hand arterial perfusion. This study includes adult patients with chronic upper limb ischemia and healthy volunteers without cardiovascular risk factors. HAT was measured in 4 different hand arteries. A standard descriptive analysis was performed, along with comparisons using the Mann-Whitney U test, when applicable. This study received institutional review board approval, and no study-related procedures were performed prior to signing the written informed consent. This research complied with the Declaration of Helsinki, Good Clinical Practice guidelines, and Spanish regulatory requirements. Results: As of June 2023, 30 participants were enrolled in the study, comprising 15 patients and 15 healthy volunteers, resulting in a total of 15 ischemic and 30 nonischemic hands. Data analyses were concluded in late November 2023, and results were sent for publication in February 2024. The manuscript containing the results was accepted in May 2024 and published online in July 2024, becoming available in PubMed in December 2024. The results have already been made available to the scientific community prior to the submission of this protocol. This study protocol was submitted for publication in July 2024 to enhance transparency and to offer comprehensive methodological insight into the HAT technique. No additional analyses beyond those reported in the published study are planned. Conclusions: This study presents the first systematic evaluation of HAT measurements by using vascular DUS as a novel diagnostic tool for chronic upper limb ischemia. By comparing ischemic and nonischemic hands, this study aims to establish preliminary cutoff values that may aid clinical decision-making. Although prior studies have only reported HAT measurements in case reports, this study provides quantitative data on its feasibility and potential clinical application. Despite its small sample size, which limits subgroup analysis and generalizability, the study serves as a foundation for future research by providing essential data for refining cutoff values and informing sample size calculations for larger studies. Although examiner dependence could introduce systematic bias, the standardized methodology ensures consistency across all measurements. Ultimately, HAT may emerge as a quick, noninvasive diagnostic tool for chronic upper limb ischemia, potentially complementing existing nonstandardized methods such as the digital-brachial index, digital pressures, and plethysmography. Trial Registration: ClinicalTrials.gov NCT05977725; https://clinicaltrials.gov/study/NCT05977725 International Registered Report Identifier (IRRID): RR1-10.2196/64450
- 21 August 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e64450
Open AccessHemodynamic Assessment of Arterial Perfusion by Using the Ultrasonographic Hand Acceleration Time: Protocol for a Cross-Sectional Prospective Descriptive Study
Background: Several noninvasive methods can be used to assess hand perfusion, but none have been standardized for diagnosing chronic upper limb ischemia. One potentially useful diagnostic tool for this purpose is the ultrasonographic hand acceleration time (HAT), although it still requires characterization and validation. Objective: This study aims to describe the technique for assessing hand perfusion through HAT while quantifying it in patients with chronic upper limb ischemia and healthy volunteers. Methods: This prospective, cross-sectional, and descriptive study evaluates HAT measurements by using vascular duplex ultrasound (DUS), a novel technique for assessing hand arterial perfusion. This study includes adult patients with chronic upper limb ischemia and healthy volunteers without cardiovascular risk factors. HAT was measured in 4 different hand arteries. A standard descriptive analysis was performed, along with comparisons using the Mann-Whitney U test, when applicable. This study received institutional review board approval, and no study-related procedures were performed prior to signing the written informed consent. This research complied with the Declaration of Helsinki, Good Clinical Practice guidelines, and Spanish regulatory requirements. Results: As of June 2023, 30 participants were enrolled in the study, comprising 15 patients and 15 healthy volunteers, resulting in a total of 15 ischemic and 30 nonischemic hands. Data analyses were concluded in late November 2023, and results were sent for publication in February 2024. The manuscript containing the results was accepted in May 2024 and published online in July 2024, becoming available in PubMed in December 2024. The results have already been made available to the scientific community prior to the submission of this protocol. This study protocol was submitted for publication in July 2024 to enhance transparency and to offer comprehensive methodological insight into the HAT technique. No additional analyses beyond those reported in the published study are planned. Conclusions: This study presents the first systematic evaluation of HAT measurements by using vascular DUS as a novel diagnostic tool for chronic upper limb ischemia. By comparing ischemic and nonischemic hands, this study aims to establish preliminary cutoff values that may aid clinical decision-making. Although prior studies have only reported HAT measurements in case reports, this study provides quantitative data on its feasibility and potential clinical application. Despite its small sample size, which limits subgroup analysis and generalizability, the study serves as a foundation for future research by providing essential data for refining cutoff values and informing sample size calculations for larger studies. Although examiner dependence could introduce systematic bias, the standardized methodology ensures consistency across all measurements. Ultimately, HAT may emerge as a quick, noninvasive diagnostic tool for chronic upper limb ischemia, potentially complementing existing nonstandardized methods such as the digital-brachial index, digital pressures, and plethysmography. Trial Registration: ClinicalTrials.gov NCT05977725; https://clinicaltrials.gov/study/NCT05977725 International Registered Report Identifier (IRRID): RR1-10.2196/64450
- 26 June 2025
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 35 (6) , 2277-2289
Blepharospasm management in Schwartz-Jampel syndrome: A systematic review
Background: Blepharospasm is one of the most limiting symptoms in patients with Schwartz-Jampel syndrome and can affect early visual development, causing amblyopia and leading to disability. There is no consensus on the optimal management of blepharospasm in these patients. This systematic review aims to evaluate the current evidence for the appropriate management strategies for blepharospasm in Schwartz-Jampel syndrome. Methods: This was a prospective register of systematic reviews (PROSPERO)-registered (CRD42024569495), Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline-adherent systematic review. Databases searched include Medline (PubMed), Scopus, and Web of Science from any time to February 1st, 2025. All scientific manuscripts published discussing the management of blepharospasm in patients with Schwartz-Jampel syndrome were included. A novel therapeutic algorithm has been developed and proposed. Results: From an initial number of 59 articles, 15 of them were included. No clinical trials nor observational studies were found. All these 15 articles were case series or case reports (quality of evidence: 4 or 5), involving 21 patients. A great heterogeneity in how to manage blepharospasm in Schwartz-Jampel syndrome was gathered. Therapeutic options included oral drugs (sodium channel blockers: carbamazepine, phenytoin, and procainamide), botulinum-toxin-A, and eyelid surgery (orbicularis myectomy). The management algorithm proposal is oral sodium channel blockers as the first option and eyelid surgery as the second option treatment. Botulinum-toxin-A might be considered a therapeutic step prior to surgery. Conclusions: The published evidence regarding management strategies for blepharospasm in Schwartz-Jampel syndrome is scarce and of low quality. Since this nosology is a very rare disease, efforts should be promoted to conduct clinical research and a consensus document for the management of blepharospasm.
- 26 June 2025
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 35 (6) , 2277-2289
Blepharospasm management in Schwartz-Jampel syndrome: A systematic review
Background: Blepharospasm is one of the most limiting symptoms in patients with Schwartz-Jampel syndrome and can affect early visual development, causing amblyopia and leading to disability. There is no consensus on the optimal management of blepharospasm in these patients. This systematic review aims to evaluate the current evidence for the appropriate management strategies for blepharospasm in Schwartz-Jampel syndrome. Methods: This was a prospective register of systematic reviews (PROSPERO)-registered (CRD42024569495), Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline-adherent systematic review. Databases searched include Medline (PubMed), Scopus, and Web of Science from any time to February 1st, 2025. All scientific manuscripts published discussing the management of blepharospasm in patients with Schwartz-Jampel syndrome were included. A novel therapeutic algorithm has been developed and proposed. Results: From an initial number of 59 articles, 15 of them were included. No clinical trials nor observational studies were found. All these 15 articles were case series or case reports (quality of evidence: 4 or 5), involving 21 patients. A great heterogeneity in how to manage blepharospasm in Schwartz-Jampel syndrome was gathered. Therapeutic options included oral drugs (sodium channel blockers: carbamazepine, phenytoin, and procainamide), botulinum-toxin-A, and eyelid surgery (orbicularis myectomy). The management algorithm proposal is oral sodium channel blockers as the first option and eyelid surgery as the second option treatment. Botulinum-toxin-A might be considered a therapeutic step prior to surgery. Conclusions: The published evidence regarding management strategies for blepharospasm in Schwartz-Jampel syndrome is scarce and of low quality. Since this nosology is a very rare disease, efforts should be promoted to conduct clinical research and a consensus document for the management of blepharospasm.
- Open Access
Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant
We used the data from a successful therapeutic assay that used icatibant in patients with hypoxemic COVID-19 pneumonia (the ICAT·COVID trial) to explore pathophysiological mechanisms. We performed concurrent-type, criterion-related validity analyses to assess the discriminative ability of a panel of nine potential serum markers (interleukin 6, ferritin, lactate dehydrogenase, C reactive protein, fibrin fragment D (D-dimer), complement 1 esterase inhibitor (antigenic and functional), complement 4 factor, and lymphocyte count) to predict the clinical milestones. Consistent with previous research, we evidenced a significant relationship between interleukin 6, lactate dehydrogenase and the lymphocyte count, and the clinical events. Furthermore, exposure to icatibant, a bradykinin B2 receptor antagonist (which improved pneumonia and mortality in the aforementioned randomised trial), attenuated this relationship, although this effect faded over time. The results reinforce the key role that the angiotensin-converting enzyme 2 has on COVID-19 pathophysiology as a point of convergence between the renin–angiotensin and kallikrein–kinin systems. This was shown clinically by the successful blocking of inflammatory pathways by icatibant at the bradykinin effector loop level early during the acute hyperinflammatory stage of the disease.
Open AccessPathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant
We used the data from a successful therapeutic assay that used icatibant in patients with hypoxemic COVID-19 pneumonia (the ICAT·COVID trial) to explore pathophysiological mechanisms. We performed concurrent-type, criterion-related validity analyses to assess the discriminative ability of a panel of nine potential serum markers (interleukin 6, ferritin, lactate dehydrogenase, C reactive protein, fibrin fragment D (D-dimer), complement 1 esterase inhibitor (antigenic and functional), complement 4 factor, and lymphocyte count) to predict the clinical milestones. Consistent with previous research, we evidenced a significant relationship between interleukin 6, lactate dehydrogenase and the lymphocyte count, and the clinical events. Furthermore, exposure to icatibant, a bradykinin B2 receptor antagonist (which improved pneumonia and mortality in the aforementioned randomised trial), attenuated this relationship, although this effect faded over time. The results reinforce the key role that the angiotensin-converting enzyme 2 has on COVID-19 pathophysiology as a point of convergence between the renin–angiotensin and kallikrein–kinin systems. This was shown clinically by the successful blocking of inflammatory pathways by icatibant at the bradykinin effector loop level early during the acute hyperinflammatory stage of the disease.
- Open Access
- 1 April 2025
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 19, 1237-1246
Biomechanical Corneal Parameters in Eyes With Chronic Ocular Hypotony and in Non-Hypotonic Eyes. Self-Controlled Case Series Study
Introduction: There are no available data concerning corneal parameters in patients with chronic ocular hypotony. Our purpose is to provide evidence and clinical correlation on the biomechanical corneal changes in chronic hypotonic eyes. Patients and Methods: A single-center, transversal, self-controlled case series study was conducted involving patients with at least one chronic hypotonic eye (defined as an intraocular pressure ≤ 6.5 mmHg measured on three separate occasions for at least three months). The chronic hypotonic eye was the case and the contralateral eye the control (non-hypotonic eye). We collected data from baseline characteristic and intraocular pressure (mmHg). Biomechanical corneal parameters measured by Corvis ST: deformation amplitude ratio (mm), Ambrósio’s relational thickness (μm), stiffness parameter at first applanation (mmHg/mm), Integrated radius (mm− 1), stress-strain index, pachymetry (μm), and in addition macular folds were recorded as well. A descriptive and exploratory analysis was performed. Results: Between November 2021 and July 2023, a total of 16 consecutive patients (7 men, 9 women; age [median (range)]: 72 (62– 84)), diagnosed with chronic ocular hypotony in one eye were included: 16 chronic hypotonic eyes and 16 non-hypotonic eyes. Hypotonic versus non-hypotonic eyes [median (range)]: intraocular pressure: 4 (2– 6) mmHg, 16 (8– 38) mmHg; deformation amplitude ratio: 5.6 (4.3– 6.6) mm, 4.7 (3.9– 5.5) mm, p-value= 0.002; Ambrósio’s relational thickness: 482 (263– 932) μm, 530 (210– 818) μm, p-value: 0.845; stiffness parameter at first applanation: 61.5 (39– 100) mmHg/mm, 113 (68– 130) mmHg/mm, p-value: < 0.001; Integrated radius: 10.9 mm− 1 (6.3– 16.8), 7.9 mm− 1 (6.4– 10.5), p-value: < 0.001; stress-strain index: 0.7 (− 0.2– 4.9), 1.1 (− 2.7– 5.6), p-value: 0.034; pachymetry 509 (456– 617) μm, 512 (436– 775) μm, p-value: 0.637; and macular folds: 7/16, 0/16, p-value: < 0.001. Conclusions: Chronic hypotonic eyes (eyes with a low intraocular pressure) present biomechanical corneal changes with respect to non-hypotonic eyes, mainly in deformation amplitude ratio, stiffness parameter at first applanation, stress-strain index and Ambrósio’s relational thickness parameters. These biomechanical corneal changes could reflect softer, more elastic and deformable scleras, which at its turn can bear higher risk of hypotony maculopathy.
- 1 April 2025
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 19, 1237-1246
Open AccessBiomechanical Corneal Parameters in Eyes With Chronic Ocular Hypotony and in Non-Hypotonic Eyes. Self-Controlled Case Series Study
Introduction: There are no available data concerning corneal parameters in patients with chronic ocular hypotony. Our purpose is to provide evidence and clinical correlation on the biomechanical corneal changes in chronic hypotonic eyes. Patients and Methods: A single-center, transversal, self-controlled case series study was conducted involving patients with at least one chronic hypotonic eye (defined as an intraocular pressure ≤ 6.5 mmHg measured on three separate occasions for at least three months). The chronic hypotonic eye was the case and the contralateral eye the control (non-hypotonic eye). We collected data from baseline characteristic and intraocular pressure (mmHg). Biomechanical corneal parameters measured by Corvis ST: deformation amplitude ratio (mm), Ambrósio’s relational thickness (μm), stiffness parameter at first applanation (mmHg/mm), Integrated radius (mm− 1), stress-strain index, pachymetry (μm), and in addition macular folds were recorded as well. A descriptive and exploratory analysis was performed. Results: Between November 2021 and July 2023, a total of 16 consecutive patients (7 men, 9 women; age [median (range)]: 72 (62– 84)), diagnosed with chronic ocular hypotony in one eye were included: 16 chronic hypotonic eyes and 16 non-hypotonic eyes. Hypotonic versus non-hypotonic eyes [median (range)]: intraocular pressure: 4 (2– 6) mmHg, 16 (8– 38) mmHg; deformation amplitude ratio: 5.6 (4.3– 6.6) mm, 4.7 (3.9– 5.5) mm, p-value= 0.002; Ambrósio’s relational thickness: 482 (263– 932) μm, 530 (210– 818) μm, p-value: 0.845; stiffness parameter at first applanation: 61.5 (39– 100) mmHg/mm, 113 (68– 130) mmHg/mm, p-value: < 0.001; Integrated radius: 10.9 mm− 1 (6.3– 16.8), 7.9 mm− 1 (6.4– 10.5), p-value: < 0.001; stress-strain index: 0.7 (− 0.2– 4.9), 1.1 (− 2.7– 5.6), p-value: 0.034; pachymetry 509 (456– 617) μm, 512 (436– 775) μm, p-value: 0.637; and macular folds: 7/16, 0/16, p-value: < 0.001. Conclusions: Chronic hypotonic eyes (eyes with a low intraocular pressure) present biomechanical corneal changes with respect to non-hypotonic eyes, mainly in deformation amplitude ratio, stiffness parameter at first applanation, stress-strain index and Ambrósio’s relational thickness parameters. These biomechanical corneal changes could reflect softer, more elastic and deformable scleras, which at its turn can bear higher risk of hypotony maculopathy.